<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01482104</url>
  </required_header>
  <id_info>
    <org_study_id>EC-004</org_study_id>
    <secondary_id>2011-004797-28</secondary_id>
    <nct_id>NCT01482104</nct_id>
  </id_info>
  <brief_title>New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)</brief_title>
  <official_title>A Randomized Controlled Blinded Multi-centre Study of Photodynamic Therapy With Methyl-aminolevulinate Comparing a Simplified Regime With the Approved Regime in Patients With Clinical Low-risk Superficial and Nodular Basal Cell Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akershus Dermatological Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Førde Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hudlegekontoret Lillehammer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hudlegene på Holtet DA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Basal cell carcinoma (BCC) is the most common malignant skin lesion in white adults. It is a
      slow-growing tumour which despite low metastatic potential may cause significant local tissue
      destruction and patient morbidity. Methyl aminolevulinate cream plus photodynamic therapy
      (MAL-PDT) for BCC is currently approved for a procedure using 2 treatment sessions 1 week
      apart. This procedure is considered quite time- and resource-consuming. Introducing a single
      treatment session, with a new PDT session for treatment failures after 3 months, might
      represent an attractive simplification.

      This randomised controlled single-blinded multi-centre study primarily aims to compare BCC
      lesion response rate of two treatment schedules: (a) 1 single treatment of Metvix-PDT with
      re-treatment of non-complete responders by 3 months, and (b) the usual schedule of 2 standard
      Metvix(R) PDT treatments 1 week apart.

      Secondary objectives are to investigate the treatment response in relation to clinical and
      histological tumour characteristics such as tumour thickness, subtype and immunohistochemical
      markers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2012</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lesions response rate</measure>
    <time_frame>3 years</time_frame>
    <description>Number of lesions in clinical complete response at follow-up</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">277</enrollment>
  <condition>Skin Neoplasms</condition>
  <condition>Carcinoma, Basal Cell</condition>
  <arm_group>
    <arm_group_label>MAL-PDT re-treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 treatment of MAL-PDT with re-treatment of non-complete responders</description>
  </arm_group>
  <arm_group>
    <arm_group_label>usual MAL-PDT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 MAL-PDT treatments 1 week apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAL-PDT re-treatment</intervention_name>
    <description>a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months</description>
    <arm_group_label>MAL-PDT re-treatment</arm_group_label>
    <other_name>Methyl-aminolevulinate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>usual MAL-PDT</intervention_name>
    <description>schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.</description>
    <arm_group_label>usual MAL-PDT</arm_group_label>
    <other_name>Methyl-aminolevulinate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male/female above 18 years of age

          -  written informed consent

          -  1 or more primary histologically verified BCC, clinically assessed as of either
             superficial of nodular type

        Exclusion Criteria:

          -  pregnancy

          -  breastfeeding

          -  Gorlin's syndrome

          -  porphyria

          -  xeroderma pigmentosum

          -  history of arsenic exposure

          -  known allergy to MAL

          -  concomitant treatment with immunosuppressive medication

          -  physical or mental conditions that most likely will prevent patients attending
             follow-up sessions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magne Børset, PhD prof</last_name>
    <role>Study Director</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept Dermatology, Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hospital Førde</name>
      <address>
        <city>Førde</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudlegekontoret Lillehammer AS</name>
      <address>
        <city>Lillehammer</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akerskus Dermatological Centre</name>
      <address>
        <city>Lørenskog</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept Dermatology, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept Surgery, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudlegen på Holtet</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept Dermato-Venereology, Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cancer Research and Molecular Medicine, NTNU</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2011</study_first_submitted>
  <study_first_submitted_qc>November 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2011</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Photochemotherapy</keyword>
  <keyword>methyl 5-aminolevulinate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

